Compass Pathways (NASDAQ:CMPS) Announces Quarterly Earnings Results, Misses Estimates By $1.49 EPS

Compass Pathways (NASDAQ:CMPS) announced its quarterly earnings data on Wednesday. The company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49), FiscalAI reports.

Here are the key takeaways from Compass Pathways’ conference call:

• COMP360 delivered statistically significant positive Phase III results in treatment-resistant depression, with rapid symptom reduction and durability demonstrated through six months; management says the clinical and regulatory profile is now substantially de-risked.
• COMPASS expects to complete its rolling NDA submission to the FDA in the fourth quarter of 2026, with some modules already under review, and believes the recently finalized psychedelic guidance will not materially affect its ongoing approval process.
• The company anticipates a launch in the first half of 2027, but timing remains fluid because federal DEA and state rescheduling must follow potential FDA approval; management expects DEA rescheduling could occur within 90 days, though the exact timing is uncertain.
• COMPASS reported $433 million in cash as of June 30, which management believes funds operations through launch and into 2028, while commercial preparations include sales-force recruiting, payer engagement, site training, and plans to address roughly 8,000 interventional psychiatry centers.
• The company is continuing to collect 52-week safety data for both Phase III studies and expects to provide the full data set to the FDA during review; it is also restarting investigator-initiated studies in areas such as OCD while prioritizing the TRD approval and launch.

Compass Pathways Trading Up 11.7%

Shares of CMPS stock traded up $1.38 during trading hours on Wednesday, hitting $13.18. 5,801,913 shares of the company’s stock traded hands, compared to its average volume of 3,739,720. The stock has a market cap of $1.78 billion, a PE ratio of -4.17 and a beta of 2.50. Compass Pathways has a 12 month low of $3.97 and a 12 month high of $15.40. The stock’s 50 day simple moving average is $12.51 and its 200 day simple moving average is $9.22. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Institutional Investors Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently modified their holdings of CMPS. Corient Private Wealth LLC boosted its holdings in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after purchasing an additional 1,200 shares during the last quarter. Conservest Capital Advisors Inc. grew its stake in Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after buying an additional 5,000 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways during the 4th quarter valued at $38,000. Raymond James Financial Inc. lifted its holdings in Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares in the last quarter. Finally, Advisory Services Network LLC bought a new stake in shares of Compass Pathways during the third quarter valued at about $41,000. Institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on CMPS shares. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target on the stock in a research report on Wednesday, July 8th. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a research report on Tuesday, July 7th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.36.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.